GHK-Cu
Summary
GHK-Cu is the copper complex of the naturally occurring tripeptide GHK. Its human elimination half-life after injection is not established by the primary studies reviewed here. An original intravenous rat study measured free GHK and its metabolite, while excised-skin experiments measured copper retention. Neither result provides a human injectable GHK-Cu half-life.
Also known as: Copper Peptide, Copper Tripeptide-1, GHK-Copper
What is GHK-Cu’s half-life?
No reliable numerical human elimination half-life for injected GHK-Cu was established by the primary studies reviewed here. Plasma elimination, endogenous GHK concentration, copper binding, tissue retention and biological effect duration answer different questions.
Measured Elimination: Free GHK in Rats
- Endo, Miyagi and Ujiie developed an assay for GHK and its metabolite His-Lys after a single intravenous dose in rats. They reported rapid conversion of GHK to His-Lys and rapid loss of the metabolite. This is free-GHK animal evidence, not human pharmacokinetics of the copper complex (PMID 9187381; DOI 10.1016/S0378-4347(96)00460-4).
- The accessible abstract does not report a numerical elimination half-life. It cannot support a precise human value, a subcutaneous absorption curve or an injection interval.
Tissue Retention: Copper Is Not Intact GHK-Cu
- Hostynek et al. applied a copper-tripeptide preparation to excised human skin in diffusion cells over 48 hours and measured copper by ICP-MS. Copper retained in skin is not a measurement of intact GHK-Cu residence time or plasma elimination half-life (PMID 20721598; DOI 10.1007/s00011-010-0238-9).
- A separate microneedle experiment measured peptide and copper as separate endpoints. Its in vitro permeation results do not establish human systemic bioavailability or clinical half-life (PMID 25690343).
Endogenous Levels and Biological Effects
- A concentration measured in endogenous plasma is not an elimination half-life after dosing. Reports about age-related GHK levels should not be presented as concentration–time data for injected GHK-Cu.
- Collagen synthesis or wound outcomes may be measured long after an exposure. Such downstream effects cannot determine how long intact complex remains in circulation. Human dose, route-specific absorption and effect duration require direct clinical measurements.
Original studies: Endo T, Miyagi M, Ujiie A (1997) ; Hostynek JJ, Dreher F, Maibach HI (2011) ; Li H, Low YS, Chong HP, et al. (2015)
Key Findings at a Glance
- • The reviewed primary evidence does not establish a numerical half-life for injected GHK-Cu in humans.
- • The original intravenous rat assay measured free GHK and His-Lys, a different question from the elimination of the copper complex in people.
- • Excised-skin experiments measured copper retention; this is not intact-peptide residence time or clinical half-life.
- • Fibroblast and rat wound studies support preclinical matrix-remodeling activity without validating a universal topical or injection regimen.
GHK-Cu Overview & Molecular Profile
GHK-Cu is a copper-chelating tripeptide (Gly-His-Lys complexed with Cu²⁺) studied for extracellular-matrix remodeling and wound repair. Endogenous GHK in plasma, administered free GHK, and the copper complex are related but distinct analytes. Fibroblast and rat wound experiments support preclinical biological activity; they do not establish a human injectable half-life or an optimal topical concentration.
Mechanism of Action: Cellular Health & Telomere Research
GHK-Cu has been studied for effects on extracellular-matrix production and remodeling. Original fibroblast experiments reported stimulation of collagen synthesis, and rat wound-chamber work reported connective-tissue accumulation. Copper binding and model-specific cellular responses do not establish clinical efficacy or pharmacokinetics.
Research-Observed Effects
Collagen Synthesis in Culture
Moderate ResearchMaquart et al. (1988) reported stimulation of collagen synthesis in fibroblast cultures by GHK-Cu. This is evidence of biological activity in a cell system, not a quantitative prediction of changes in human skin after cosmetic or injectable use.
Connective-Tissue Accumulation in Rat Wounds
Preliminary ResearchMaquart et al. (1993) studied GHK-Cu in implanted wound chambers in rats and reported increased connective-tissue components. The experimental model does not establish efficacy for human chronic wounds, an optimal cosmetic concentration or a systemic dose.
Research Protocol Doses Reported in Published Literature
Research Disclaimer: Doses reported below are from published preclinical research protocols. GHK-Cu is not approved by the US FDA for human use; regulatory status can differ in other countries, so see the regulatory status note in the safety section of this page. This information is provided for research reference only and does not constitute a dosing recommendation.
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Topical / human injection | Not established here | Not established | No general regimen can be inferred from the cited cell, rat or excised-skin experiments |
All doses above are reported from published research protocols using laboratory subjects. Refer to the cited studies in the Research Studies section above for original source data.
Research Studies & References
In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds
Maquart FX, Bellon G, Chaqour B, et al.
Journal of Clinical Investigation (1993)
Original rat wound-chamber experiment reporting increased connective-tissue accumulation with GHK-Cu. This is a local preclinical model, not evidence for a human systemic dose or elimination half-life.
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+
Maquart FX, et al.
FEBS Letters (1988)
Original fibroblast-culture study reporting stimulation of collagen synthesis by GHK-Cu; not a human cosmetic dose-ranging or pharmacokinetic study.
Simultaneous determination of glycyl-L-histidyl-L-lysine and its metabolite, L-histidyl-L-lysine, in rat plasma by high-performance liquid chromatography with post-column derivatization
Endo T, Miyagi M, Ujiie A
Journal of Chromatography B (1997)
Original assay applied to free GHK after a single intravenous dose in rats. Rapid conversion to His-Lys; not human injected GHK-Cu.
Human skin penetration of a copper tripeptide in vitro as a function of skin layer
Hostynek JJ, Dreher F, Maibach HI
Inflammation Research (2011)
Original diffusion-cell experiment in excised human skin; quantified copper, not intact circulating GHK-Cu.
Comparative Research
Explore in-depth research analyses and comparative studies featuring GHK-Cu.
Technical Deep Dives
GLOW Stack: A Scientific Analysis of GHK-Cu, BPC-157, and TB-500 Combination Research
The GLOW Stack is a three-peptide research combination consisting of GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound-157), and TB-500 (a synthetic fragment of Thymosin Beta-4), typically described in a 5:1:1 ratio by mass with GHK-Cu as the majority component. It extends the two-peptide Wolverine Stack (BPC-157 + TB-500) by adding GHK-Cu, a copper-binding tripeptide with documented effects on extracellular matrix gene expression. While each individual peptide has a body of preclinical research, no published study has evaluated the three-peptide GLOW combination together, and its purported synergistic benefits remain entirely theoretical.
How GHK-Cu Binds Copper and Changes Gene Expression
GHK-Cu binds copper(II) through the tripeptide glycyl-L-histidyl-L-lysine. Copper-binding chemistry, cell responses and preclinical matrix-remodeling findings are distinct from clinical pharmacokinetics. Gene-expression studies do not establish whole-body rejuvenation or a human injectable half-life; the size and direction of an effect depend on the model and endpoint.
Comparative Clinical Analysis
GHK-Cu vs BPC-157: Copper Peptide vs Gastric Peptide Comparison for Tissue Repair Research
GHK-Cu and BPC-157 are two of the most researched peptides for tissue repair, with distinct but potentially complementary mechanisms. GHK-Cu, a naturally occurring copper-binding tripeptide, excels in skin rejuvenation, collagen remodeling, and topical wound healing through copper-dependent enzyme activation. BPC-157, a stable gastric pentadecapeptide, demonstrates broader systemic healing effects across multiple tissue types including tendons, muscles, and the gastrointestinal tract through angiogenic and growth factor pathways. GHK-Cu is well-suited for dermatological applications, while BPC-157 shows greater versatility for internal tissue repair.
GHK-Cu vs Epithalon: Anti-Aging Peptide Comparison | Peptpedia
GHK-Cu and Epithalon are two well-characterized anti-aging peptides targeting different biological mechanisms. GHK-Cu is a naturally occurring copper tripeptide that modulates gene expression, promotes collagen synthesis, and has the most extensive human application through topical cosmeceuticals. Epithalon is a pineal tetrapeptide studied for telomerase activation and telomere elongation, primarily in Russian research contexts.
TB-500 vs GHK-Cu: Cell Migration vs Gene Modulation in Regenerative Peptide Research
TB-500 and GHK-Cu are both studied for tissue repair, but they represent two different biological strategies. TB-500 is a synthetic fragment modeled on Thymosin Beta-4 (Tβ4), a 43-amino-acid G-actin-sequestering peptide that drives cell migration and activates the PINCH/ILK/Akt survival pathway — the mechanism behind its landmark cardiac repair data in a mouse myocardial infarction model. GHK-Cu is an endogenous copper-binding tripeptide whose plasma levels decline with age and which modulates the expression of hundreds of genes tied to extracellular matrix remodeling, antioxidant defense, and inflammation control. Tβ4's evidence runs deeper in cardiac and compromised-wound models, including two Phase 2 dermal trials of the full-length peptide; GHK-Cu's runs deepest in skin and matrix remodeling, supported by gene-profiling data but mostly cosmetic-grade human studies. Nearly all Tβ4 findings derive from the full-length protein, and how faithfully the TB-500 fragment reproduces them remains an open question.
Frequently Asked Questions
Which chemical form do the identifiers describe?
The formula, mass and CAS shown here refer to prezatide copper as represented by PubChem CID 71587328 (net charge +1). Other records use different protonation states, and salts or formulated products can have different compositions and masses. These identifiers do not specify every preparation sold as GHK-Cu.
What is GHK-Cu’s half-life?
A numerical human elimination half-life after injection is not established by the primary studies reviewed here. Endo et al. measured free GHK after intravenous dosing in rats; Hostynek et al. measured copper in excised skin. Neither is human injectable GHK-Cu pharmacokinetics.
Does skin retention mean GHK-Cu has a long plasma half-life?
No. The excised-skin experiment measured copper, which can exchange binding partners, rather than intact circulating GHK-Cu. Tissue copper, peptide concentration and biological effects are different endpoints.
Do endogenous GHK levels determine an injection schedule?
No. A natural plasma concentration or age-related difference does not establish absorption, clearance or an appropriate dose interval after administering a copper-peptide preparation.
What topical concentration is supported?
The primary papers cited here do not establish a universal cosmetic percentage or application frequency. Experimental solutions, formulated products and percentages of a premixed ingredient are not interchangeable.
Can GHK-Cu be used systemically?
Preclinical systemic or local administration does not establish a safe or effective human injection regimen. The cited studies do not validate the fixed milligram doses or frequencies often circulated online.
Does copper binding rule out toxicity?
No. Binding chemistry alone cannot establish safety for a particular dose, formulation or route. A copper measurement or the natural presence of GHK in plasma is not a clinical toxicity assessment.
Does research support tissue repair?
Original fibroblast and rat wound studies support preclinical extracellular-matrix activity. Their endpoints do not establish the size or duration of a clinical effect in people.
Related Peptides
View allBPC-157
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types.
TB-500
TB-500 is the N-terminally acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ, CAS 885340-08-9), identified analytically in TB-500 product by HPLC/high-resolution MS (PMID 22962027). It is studied for tissue repair, cell migration, and blood vessel formation. Product content is not reliable: a 2023 analysis of TB500/TB1000 sold online found contents inconsistent with the label, including full-length 43-residue thymosin beta-4 in place of the heptapeptide (PMID 36482504).
Epithalon
Epithalon is a synthetic tetrapeptide based on the natural peptide Epithalamin produced by the pineal gland. It has been studied for effects on telomerase activity and longevity.
AHK-Cu
AHK-Cu (copper tripeptide-3) is the copper complex of the tripeptide Ala-His-Lys, a synthetic analog of GHK-Cu studied for hair follicle and skin applications.
Related Comparisons
GHK-Cu vs BPC-157
GHK-Cu and BPC-157 are two of the most researched peptides for tissue repair, with distinct but potentially complementary mechanisms. GHK-Cu, a naturally occurring copper-binding tripeptide, excels in skin rejuvenation, collagen remodeling, and topical wound healing through copper-dependent enzyme activation. BPC-157, a stable gastric pentadecapeptide, demonstrates broader systemic healing effects across multiple tissue types including tendons, muscles, and the gastrointestinal tract through angiogenic and growth factor pathways. GHK-Cu is well-suited for dermatological applications, while BPC-157 shows greater versatility for internal tissue repair.
GHK-Cu vs Epithalon
GHK-Cu and Epithalon are two well-characterized anti-aging peptides targeting different biological mechanisms. GHK-Cu is a naturally occurring copper tripeptide that modulates gene expression, promotes collagen synthesis, and has the most extensive human application through topical cosmeceuticals. Epithalon is a pineal tetrapeptide studied for telomerase activation and telomere elongation, primarily in Russian research contexts.
TB-500 vs GHK-Cu
TB-500 and GHK-Cu are both studied for tissue repair, but they represent two different biological strategies. TB-500 is a synthetic fragment modeled on Thymosin Beta-4 (Tβ4), a 43-amino-acid G-actin-sequestering peptide that drives cell migration and activates the PINCH/ILK/Akt survival pathway — the mechanism behind its landmark cardiac repair data in a mouse myocardial infarction model. GHK-Cu is an endogenous copper-binding tripeptide whose plasma levels decline with age and which modulates the expression of hundreds of genes tied to extracellular matrix remodeling, antioxidant defense, and inflammation control. Tβ4's evidence runs deeper in cardiac and compromised-wound models, including two Phase 2 dermal trials of the full-length peptide; GHK-Cu's runs deepest in skin and matrix remodeling, supported by gene-profiling data but mostly cosmetic-grade human studies. Nearly all Tβ4 findings derive from the full-length protein, and how faithfully the TB-500 fragment reproduces them remains an open question.
Related Research
GLOW Stack: A Scientific Analysis of GHK-Cu, BPC-157, and TB-500 Combination Research
The GLOW Stack is a three-peptide research combination consisting of GHK-Cu (glycyl-L-histidyl-L-lysine copper complex), BPC-157 (Body Protection Compound-157), and TB-500 (a synthetic fragment of Thymosin Beta-4), typically described in a 5:1:1 ratio by mass with GHK-Cu as the majority component. It extends the two-peptide Wolverine Stack (BPC-157 + TB-500) by adding GHK-Cu, a copper-binding tripeptide with documented effects on extracellular matrix gene expression. While each individual peptide has a body of preclinical research, no published study has evaluated the three-peptide GLOW combination together, and its purported synergistic benefits remain entirely theoretical.
How GHK-Cu Binds Copper and Changes Gene Expression
GHK-Cu binds copper(II) through the tripeptide glycyl-L-histidyl-L-lysine. Copper-binding chemistry, cell responses and preclinical matrix-remodeling findings are distinct from clinical pharmacokinetics. Gene-expression studies do not establish whole-body rejuvenation or a human injectable half-life; the size and direction of an effect depend on the model and endpoint.
Follow Peptpedia on Google
Add Peptpedia as a Preferred Source and Google can highlight our links with a "preferred" badge in your Top Stories and AI Overviews.